Meet Alfa Cytology at the Cancer R&D 2024, Nov 18-20, 2024. We look forward to connecting with you and providing expert solutions for your cancer drug development projects.
Learn More
Non-small cell lung cancer (NSCLC) originates from lung tissue and typically grows and spreads at a slower rate compared to small cell lung cancer. Alfa Cytology is a world leader in the research of lung cancer. With our extensive experience and advanced platform, we can provide the best solutions for NSCLC.
Non-small cell lung cancer accounts for approximately 80% to 85% of lung cancer. According to their origin from different types of lung cells, the main subtypes are adenocarcinoma, squamous cell carcinoma, and large cell carcinoma. Meanwhile, due to its similar treatment and prognosis, it is classified as non-small cell lung cancer.
Adenocarcinoma
Lung adenocarcinoma begins with epithelial cells in the lungs and is the most common type of non-small cell lung cancer.
Squamous Cell Carcinoma
Squamous cell carcinoma begins with flat squamous cells inside the lung airways and is usually associated with a history of smoking.
Large Cell Carcinoma
Large cell carcinoma can appear in any part of the lungs. It often grows and spreads rapidly, making treatment more difficult.
The development of therapies for NSCLC typically includes surgery, radiation therapy, chemotherapy, targeted therapy, and immunotherapy. NSCLC is usually caused by gene mutation or alteration, such as EGFR, ALK, ROS1, or KRAS mutations.
The following are a few examples of pharmaceutical companies and their pipeline development related to NSCLS. The field of therapy for NSCLC is developing rapidly.
Targets | Therapeutics | Company | Molecule Type | Phase |
---|---|---|---|---|
TK | Entrectinib | Genentech | Small molecule | |
LAG-3 | Favezelimab (MK-4280) | Merck | Monoclonal antibody | |
TGF-β1 | ABBV-151 | Abbvie | Humanized monoclonal antibody inhibitor | |
cMet | Telisotuzumab vedotin (ABBV-399) | Abbvie | Antibody-drug conjugate |
Due to the complexity of NSCLC, there are many challenges in developing effective therapies, such as tumor heterogeneity, genetic complexity and variability, and breaking through the blood-brain barrier. Therefore, Alfa Cytology is working on providing one-stop solutions, including but not limited to the following.
Models of NSCLC are used to study the biology of the disease, its progression, treatment response, and the development of new therapies. Alfa Cytology is a leading biological contract research organization (CRO). We have many years of experience in building NSCLC tumor models. Our company offers several popular NSCLC models, including but not limited to the following. Each model has its characteristics and applications.
Alfa Cytology is committed to the research and study of lung cancer and provides one-stop services. Our cancer experts have many years of experience in the development of the latest therapies for NSCLC. If you are interested in our service, please contact us for more information.
For research use only.